Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

LianBio Completes Enrollment of Phase III Trial for Cardiomyopathy Therapy

publication date: Aug 10, 2022

LianBio has completed enrollment in a China Phase III trial of mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). LianBio, a Shanghai-Princeton in-licensing company, acquired greater China rights to mavacamten from MyoKardia in a $187.5 million deal that included a stake in LianBio’s cardiology subsidiary. Earlier this year, mavacamten was approved in the US to treat patients with class II-III oHCM. LianBio expects to report topline data from the China Phase III mavacamten trial in mid-2023. More details....

Stock Symbol: (NSDQ: LIAN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital